ES3058702T3 - A vaccine for use in the prophylaxis and/or treatment of a disease - Google Patents

A vaccine for use in the prophylaxis and/or treatment of a disease

Info

Publication number
ES3058702T3
ES3058702T3 ES18762507T ES18762507T ES3058702T3 ES 3058702 T3 ES3058702 T3 ES 3058702T3 ES 18762507 T ES18762507 T ES 18762507T ES 18762507 T ES18762507 T ES 18762507T ES 3058702 T3 ES3058702 T3 ES 3058702T3
Authority
ES
Spain
Prior art keywords
vaccine
prophylaxis
disease
treatment
isd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18762507T
Other languages
English (en)
Inventor
Peter Holst
Christian Thirion
Lasse Neukirch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inprother Aps
Original Assignee
Inprother Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inprother Aps filed Critical Inprother Aps
Application granted granted Critical
Publication of ES3058702T3 publication Critical patent/ES3058702T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invención se refiere a un vector adenoviral capaz de codificar una partícula similar a virus (VLP), la cual presenta un dominio inmunosupresor (ISD) inactivo. La vacuna de la invención muestra una respuesta inmunitaria mejorada a partir de cualquiera de las vías de respuesta iniciadas por los linfocitos T CD4+ o CD8+. (Traducción automática con Google Translate, sin valor legal)
ES18762507T 2017-09-01 2018-08-30 A vaccine for use in the prophylaxis and/or treatment of a disease Active ES3058702T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201770659 2017-09-01
PCT/EP2018/073404 WO2019043127A1 (en) 2017-09-01 2018-08-30 VACCINE FOR USE IN PROPHYLAXIS AND / OR TREATMENT OF DISEASE

Publications (1)

Publication Number Publication Date
ES3058702T3 true ES3058702T3 (en) 2026-03-12

Family

ID=65526240

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18762507T Active ES3058702T3 (en) 2017-09-01 2018-08-30 A vaccine for use in the prophylaxis and/or treatment of a disease
ES19765206T Active ES3041285T3 (en) 2017-09-01 2019-08-30 A vaccine for use in the prophylaxis and/or treatment of a disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES19765206T Active ES3041285T3 (en) 2017-09-01 2019-08-30 A vaccine for use in the prophylaxis and/or treatment of a disease

Country Status (15)

Country Link
US (7) US11351247B2 (es)
EP (4) EP3676285B1 (es)
JP (3) JP7277466B2 (es)
KR (1) KR20210050558A (es)
CN (2) CN111630060B (es)
AU (1) AU2018322831B2 (es)
BR (1) BR112021003644A2 (es)
CA (1) CA3074088A1 (es)
DK (1) DK3676285T3 (es)
EA (1) EA202090548A1 (es)
ES (2) ES3058702T3 (es)
FI (1) FI3676285T3 (es)
HR (2) HRP20260041T1 (es)
PL (1) PL3676285T3 (es)
WO (2) WO2019043127A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018322831B2 (en) * 2017-09-01 2023-04-27 Inprother Aps A vaccine for use in the prophylaxis and/or treatment of a disease
JP7344300B2 (ja) 2018-09-18 2023-09-13 ブイエヌブイ ニューコ インク． Ａｒｃベースのカプシドおよびその使用
WO2020252455A1 (en) * 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
CN114867491B (zh) * 2019-11-20 2025-08-15 巴法里安诺迪克有限公司 用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒
EP4185600A4 (en) 2020-07-24 2024-12-04 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
CN112103353B (zh) * 2020-08-21 2023-07-18 中国地质大学（北京） 一种基于磷硒化锰(MnPSe3)场效应晶体管结构的光电探测器
AU2021342576A1 (en) * 2020-09-21 2023-04-06 University Of Georgia Research Foundation, Inc. PIV5-based covid-19 vaccine
US20240391979A1 (en) * 2021-09-13 2024-11-28 Achelois Biopharma, Inc. Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
WO2024219994A1 (ru) * 2023-04-16 2024-10-24 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор на основе аденовируса человека 19 серотипа и способ его применения
WO2024218400A1 (en) * 2023-04-21 2024-10-24 Inprother Aps Improved expression of surface-displayed antigens
WO2025002587A1 (en) * 2023-06-27 2025-01-02 Inprother Aps Chimeric vlp forming polypeptides comprising beta-retroviral gag
KR20260048548A (ko) * 2023-06-27 2026-04-10 인프로더 에이피에스 베타-레트로바이러스 Gag를 포함하는 키메라 VLP 형성 폴리펩타이드
CN118561966B (zh) * 2024-05-20 2025-07-11 浙江大学 人内源性逆转录病毒包膜蛋白突变体、截短体及其用途
WO2026030596A1 (en) * 2024-08-01 2026-02-05 Twilight Bioscience, Inc. Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use
WO2026030590A1 (en) * 2024-08-01 2026-02-05 Twilight Bioscience, Inc. Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use
CN119751661A (zh) * 2024-12-16 2025-04-04 浙江大学 抗herv-k102-su鼠源抗体及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
FR2780069B1 (fr) 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
CN1357050A (zh) * 1999-07-02 2002-07-03 昂尼克斯药物公司 用于治疗疾病的腺病毒载体
JP2005508154A (ja) 2001-08-15 2005-03-31 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 外套細胞リンパ腫の外套組織球から単離されたレトロウイルス
ZA200608178B (en) 2004-03-30 2008-10-29 Roussy Inst Gustave Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
DK1871391T3 (da) * 2005-03-30 2012-04-16 Viroxis Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
WO2007107156A2 (en) 2006-03-17 2007-09-27 Aarhus Universitet Chimeric viral envelopes
ZA200900379B (en) 2006-07-21 2010-08-25 Univ California Human endogenous retrovirus polypeptide compositions and methods of use thereof
WO2010022740A2 (en) 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine
WO2011056899A2 (en) * 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
US20140227311A1 (en) * 2011-08-23 2014-08-14 Skau Aps Method for Removing Immunosuppressive Properties of HIV Envelope Glycoproteins
WO2013050048A2 (en) 2011-10-07 2013-04-11 Skau Aps Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses
WO2013059426A1 (en) * 2011-10-21 2013-04-25 The Regents Of The University Of California Human endogenous retrovirus peptides, antibodies to the peptides, and methods of use thereof
DK2788372T3 (da) * 2011-12-07 2019-10-14 Viroxis S A S Muterede lentivirus-ENV-proteiner og anvendelse deraf som lægemidler
US9624510B2 (en) * 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
WO2014195510A1 (en) 2013-06-07 2014-12-11 Viroxis S.A.S. Mutated non-primate lentiviral env proteins and their use as drugs
US20190040106A1 (en) * 2015-10-01 2019-02-07 Aimvion A/S Use of human derived immunosuppressive proteins and peptides as medicaments
WO2018234576A1 (en) * 2017-06-22 2018-12-27 Institut Gustave Roussy HUMAN ENDOGENOUS RETROVIRAL PROTEIN
AU2018322831B2 (en) * 2017-09-01 2023-04-27 Inprother Aps A vaccine for use in the prophylaxis and/or treatment of a disease

Also Published As

Publication number Publication date
AU2018322831A9 (en) 2020-07-23
EP4667485A3 (en) 2026-02-18
ES3041285T3 (en) 2025-11-11
EP4450516A3 (en) 2025-01-22
JP2020531053A (ja) 2020-11-05
US12023377B2 (en) 2024-07-02
JP7277466B2 (ja) 2023-05-19
PL3676285T3 (pl) 2026-03-23
US20230181716A1 (en) 2023-06-15
JP2023100875A (ja) 2023-07-19
EP4450516A2 (en) 2024-10-23
CN111630060A (zh) 2020-09-04
EP3676285B1 (en) 2025-11-05
CN113056477A (zh) 2021-06-29
CN111630060B (zh) 2024-01-23
US20220347291A1 (en) 2022-11-03
US20240148860A1 (en) 2024-05-09
WO2020043908A1 (en) 2020-03-05
AU2018322831B2 (en) 2023-04-27
US20250186579A1 (en) 2025-06-12
EP3676285A1 (en) 2020-07-08
WO2019043127A1 (en) 2019-03-07
EP3844178A1 (en) 2021-07-07
EP4667485A2 (en) 2025-12-24
US12263214B2 (en) 2025-04-01
US20260077031A1 (en) 2026-03-19
DK3676285T3 (da) 2026-01-19
WO2019043127A9 (en) 2020-06-18
HRP20260041T1 (hr) 2026-04-10
FI3676285T3 (fi) 2025-12-18
AU2018322831A1 (en) 2020-03-12
EP3844178B1 (en) 2025-08-20
JP2025172855A (ja) 2025-11-26
HRP20251176T1 (hr) 2025-12-19
CA3074088A1 (en) 2019-03-07
EP3844178C0 (en) 2025-08-20
BR112021003644A2 (pt) 2021-05-18
JP7735344B2 (ja) 2025-09-08
US20220387580A1 (en) 2022-12-08
CN113056477B (zh) 2026-03-17
EA202090548A1 (ru) 2020-06-23
KR20210050558A (ko) 2021-05-07
US11883487B2 (en) 2024-01-30
US11351247B2 (en) 2022-06-07
US12390522B2 (en) 2025-08-19
US20200330586A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
ES3058702T3 (en) A vaccine for use in the prophylaxis and/or treatment of a disease
EA201800108A1 (ru) Вакцинные композиции для профилактики абровирусных инфекций
WO2015168379A3 (en) Combination vaccine devices and methods of killing cancer cells
PH12013502322A1 (en) Hendra and nipah virus g glycoprotein immunogenic compositions
ZA202403393B (en) Synthetic chimeric poxviruses
MX390278B (es) Formulaciones de vacuna de vial unico.
MX387985B (es) Particulas tipo virus modificadas de cmv.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
EA201890723A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге
EA201791614A1 (ru) Производные индола в качестве ингибиторов репликации вирусов денге
CO6551750A2 (es) Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
IL263979A (en) Enveloped virus resistant to complement inactivation
CL2016002577A1 (es) Compuestos macrólidos derivados de 3,4-2h,11h-10,6-(azeno)-12,16-(meteno)-1,5,11,13-benzodioxadiazaciclooctadecino; compuestos intermediarios, sin acción farmacológica; procedimiento de preparación; composiciones y combinaciones farmacológicas; útiles para el tratamiento y/o profilaxis de trastornos hiperproliferativo, enfermedades infecciosas inducidas por virus y/o enfermedades cardiovasculares.
CU20180035A7 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
MX2020005554A (es) Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
MX390304B (es) Proceso para preparar una vacuna tetravalente atenuada contra el dengue.
MX2019007973A (es) Composiciones universales de vacuna de la influenza.
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.
EA201691638A1 (ru) Новые способы индуцирования иммунного ответа
MX388635B (es) Vacunas atenuadas vivas del virus de la influenza equina
MX354758B (es) Metodos para la liberacion de las particulas similares a virus.
WO2018175580A3 (en) Development of an alternative modified live influenza b virus vaccine